Implementation of Anal Cancer Screening and Treatment in Nigeria
ConditionEducation, Medical
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorUniversity of Maryland, Baltimore
About this trial
The study is a feasibility pilot trial testing 2 types of training protocols on a single physician. The first training protocol is the current standard and was developed in high-income settings. The second training protocol will be developed so tailored to the Nigerian setting. Investigators will test if the physician performs differently in their ability to conduct anal cancer screening and treatment between the 2 training protocols.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Possess a medical degree in medical sciences (MBBS or equivalent)
At least 2-5 years of experience working with clinical HIV/AIDS community
Must be registered with the medical and dental council of Nigeria
Possess a current medical practicing license
Disqualifiers
None
Trial design
Design model
Sequential
Treatments tested in this trial
Enhanced Training on screening and treatment of HSIL (e-STH)
BehavioralTailored training developed to overcome key barriers and promote facilitators unique to implementing HSIL screening and treatment. The development will be driven by the implementation science committee over 3 iterations every 4 months for up to a year to refine the adoption of strategies with the greatest breadth to facilitate implementation.
Treatment groups
1 Participants
are divided into 2 treatment groupsGroup A: Enhanced Training on screening and treatment of HSIL (e-STH)Experimental treatment 1 intervention
Group B: Standard Screening and treatment of HSILNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
Change in HSIL detection
Evaluate change in HSIL detected between the pre and post period (standard vs e-STH)
Time frame
12 months and 30 months2
Change in HSIL treatment
Evaluate change in HSIL treated between the pre and post period (standard vs e-STH)
Time frame
12 months and 30 monthsSecondary outcomes
1
Change in Reach of intended population
Change in number screened per number eligible between the pre and post period
Time frame
12 months and 30 months2
Change in Efficacy of conducting HSIL screening and treatment
Compare number needed to screen to reach a plateau in the detection of HSIL between the pre and post period
Time frame
12 months and 30 months3
Change in Implementation of HSIL screening and treatment
Compare number of biopsies taken per screening between the pre and post period
Time frame
12 months and 30 months4
Change in Maintenance of HSIL screening and treatment
Compare number who return for a 12-month screening between the pre and post period
Time frame
18 months and 36 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Maryland, Baltimore
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov